Veracyte, Inc. (VCYT)
Largest Insider Buys in Sector
VCYT Stock Price History Chart
VCYT Stock Performance
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, …
Insider Activity of Veracyte, Inc.
Over the last 12 months, insiders at Veracyte, Inc. have bought $0 and sold $7.63M worth of Veracyte, Inc. stock.
On average, over the past 5 years, insiders at Veracyte, Inc. have bought $525,242 and sold $42.27M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $980,094 was made by Stapley Marc (Chief Executive Officer) on 2022‑06‑10.
List of Insider Buy and Sell Transactions, Veracyte, Inc.
| 2024-12-13 | Sale | Chief Executive Officer | 5,590 0.0072% | $43.42 | $242,737 | -3.71% | ||
| 2024-12-04 | Sale | Chief Scientific & Med Officer | 3,934 0.0051% | $44.09 | $173,447 | -2.52% | ||
| 2024-12-04 | Sale | SVP, General Counsel | 18,699 0.024% | $44.02 | $823,179 | -2.52% | ||
| 2024-12-03 | Sale | Chief Financial Officer | 7,000 0.009% | $43.23 | $302,622 | -1.28% | ||
| 2024-12-03 | Sale | Chief Commercial Officer-CLIA | 1,050 0.0014% | $43.25 | $45,408 | -1.28% | ||
| 2024-12-03 | Sale | VP, Chief Accounting Officer | 956 0.0012% | $43.36 | $41,452 | -1.28% | ||
| 2024-11-27 | Sale | VP, Chief Accounting Officer | 5,032 0.0065% | $42.89 | $215,834 | +0.77% | ||
| 2024-11-19 | Sale | director | 14,731 0.0188% | $38.34 | $564,768 | -0.33% | ||
| 2024-11-12 | Sale | Chief Financial Officer | 15,275 0.0198% | $38.34 | $585,663 | +12.03% | ||
| 2024-11-12 | Sale | director | 15,000 0.0195% | $38.32 | $574,830 | +12.03% | ||
| 2024-09-19 | Sale | director | 5,173 0.0067% | $35.23 | $182,263 | +3.65% | ||
| 2024-09-04 | Sale | Chief Commercial Officer-CLIA | 5,479 0.0072% | $29.78 | $163,159 | +18.12% | ||
| 2024-08-13 | Sale | director | 24,326 0.0341% | $32.04 | $779,456 | +6.20% | ||
| 2024-08-13 | Sale | director | 47,645 0.0671% | $32.20 | $1.53M | 0.00% | ||
| 2024-08-12 | Sale | director | 200 0.0003% | $30.00 | $6,001 | +14.67% | ||
| 2024-08-09 | Sale | director | 1,778 0.0024% | $30.03 | $53,391 | +17.22% | ||
| 2024-08-07 | Sale | director | 5,108 0.0075% | $30.32 | $154,883 | +26.65% | ||
| 2024-08-07 | Sale | director | 5,000 0.007% | $29.00 | $145,000 | +26.65% | ||
| 2024-07-16 | Sale | Chief Commercial Officer-CLIA | 1,277 0.0019% | $25.00 | $31,925 | +32.24% | ||
| 2024-07-16 | Sale | director | 7,500 0.0109% | $25.00 | $187,500 | +32.24% |
Insider Historical Profitability
| Stapley Marc | Chief Executive Officer | 307345 0.3966% | $41.18 | 1 | 1 | +45.22% |
| Holstein Jens | director | 27878 0.036% | $41.18 | 1 | 3 | +12.01% |
| Anderson Bonnie H | director | 42681 0.0551% | $41.18 | 4 | 51 | +38.63% |
| Brooks Julie | EVP,General Counsel, Secretary | 3122 0.004% | $41.18 | 4 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $163.65M | 9.66 | 7.38M | +3.75% | +$5.91M | <0.01 | |
| Wellington Management Company | $163.26M | 9.64 | 7.37M | +4.23% | +$6.63M | 0.03 | |
| BlackRock | $159.8M | 9.43 | 7.21M | +0.69% | +$1.1M | <0.01 | |
| ARK Investment Management LLC | $156.07M | 9.21 | 7.04M | -8.01% | -$13.58M | 0.54 | |
| State Street | $95.89M | 5.66 | 4.33M | +39.19% | +$27M | <0.01 |